Kenvue Inc.

Kenvue Inc. (KVUE) Market Cap

Kenvue Inc. has a market capitalization of $33.21B.

Financials based on reported quarter end 2025-12-28

Price: $17.32

โ–ฒ 0.03 (0.14%)

Market Cap: 33.21B

NYSE ยท time unavailable

CEO: Kirk L. Perry

Sector: Consumer Defensive

Industry: Household & Personal Products

IPO Date: 2023-05-04

Website: https://www.kenvue.com

Kenvue Inc. (KVUE) - Company Information

Market Cap: 33.21B ยท Sector: Consumer Defensive

Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.

Analyst Sentiment

60%
Buy

Based on 14 ratings

Analyst 1Y Forecast: $18.45

Average target (based on 3 sources)

Consensus Price Target

Low

$18

Median

$18

High

$19

Average

$18

Potential Upside: 4.9%

Price & Moving Averages

Loading chart...

๐Ÿ“˜ Full Research Report

โ„น๏ธ

AI-Generated Research: This report is for informational purposes only.

๐Ÿ“˜ Kenvue Inc. (KVUE) โ€” Investment Overview

๐Ÿงฉ Business Model Overview

Kenvue Inc. operates as a leading global consumer health company, focusing on the development, manufacturing, and marketing of a broad portfolio of well-known personal health, over-the-counter medicine, and wellness brands. Its offerings span categories such as self-care, skin health and beauty, and essential health, targeting everyday consumer healthcare needs. Kenvue's core brands are widely recognized and trusted, reaching households across geographies and age segments. The company leverages omnichannel distributionโ€”ranging from large retail and pharmacy partners to e-commerce platformsโ€”to maximize accessibility and penetrate both developed and emerging markets.

๐Ÿ’ฐ Revenue Model & Ecosystem

Kenvue's revenue model centers on direct product sales to consumers, primarily through wholesale and retail distribution networks, as well as digital sales channels. Its ecosystem encompasses a diverse range of products, including over-the-counter medications, skincare solutions, and hygiene products that enjoy recurring demand. While the companyโ€™s focus is predominantly on physical goods, it benefits from favorable brand loyalty and regular purchase cycles typical for consumer health items. Kenvue serves a broad spectrum of customers, from individual consumers and families to healthcare providers, maintaining a resilient and defensive revenue base across economic cycles.

๐Ÿง  Competitive Advantages

  • Brand strength: Kenvueโ€™s portfolio features several iconic, long-standing brandsโ€”deeply embedded in consumer routines for health, wellness, and hygiene.
  • Switching costs: High trust and positive consumer experiences foster brand loyalty, reducing willingness to experiment with lesser-known alternatives, especially in healthcare-related products.
  • Ecosystem stickiness: The breadth of products within overlapping health and wellness domains encourages cross-category purchasing and keeps Kenvue's products top-of-mind for regular use.
  • Scale + supply chain leverage: Operating at large global scale allows Kenvue to optimize manufacturing, procurement, and distribution, supporting competitive pricing and consistent supply.

๐Ÿš€ Growth Drivers Ahead

Kenvue is positioned to capture long-term growth through several multi-year catalysts. Increasing consumer focus on health and wellness supports demand for self-care and over-the-counter products. Ongoing innovation in product formulations and packaging, as well as digital engagement, aim to reinforce brand leadership and appeal to younger demographics. The company actively pursues geographic expansion, especially in emerging markets where urbanization and rising incomes drive market penetration. Additionally, Kenvue seeks to grow through new product launches, strategic partnerships, and targeted acquisitions within adjacent categories.

โš  Risk Factors to Monitor

Investors should be mindful of heightened competition from both multinational consumer healthcare conglomerates and agile local entrants, which can pressure pricing and market share. Regulatory changes, such as shifts in health product classifications or advertising restrictions, introduce compliance challenges and complexity. Rising input costs and supply chain disruptions could compress margins. Finally, evolving consumer preferences and the threat of innovation from non-traditional digital health platforms present potential for long-term disruption if not proactively managed.

๐Ÿ“Š Valuation Perspective

The market typically values Kenvue in line with or at a modest premium to peers in the global consumer health sector, reflective of its brand equity, portfolio defensiveness, and resilient cash generation profile. This valuation perspective often factors in the companyโ€™s ability to sustain leadership in crowded product categories and the expectation of steady, recession-resistant growth relative to more cyclical segments of the consumer market.

๐Ÿ” Investment Takeaway

Kenvue offers investors exposure to a stable, broadly diversified consumer health platform, underpinned by premium brands and robust recurring demand. The bull case centers on durable market share, innovation-led expansion, and the resilience of healthcare spending through economic cycles. The bear case emphasizes industry competition, potential margin erosion, and the need for ongoing relevance in an evolving health and wellness landscape. Ultimately, Kenvue represents a core holding opportunity for those seeking defensive, brand-driven growth, balanced by the challenges inherent to the mature consumer healthcare space.


โš  AI-generated research summary โ€” not financial advice. Validate using official filings & independent analysis.

Fundamentals Overview

Loading fundamentals overview...

๐Ÿ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-28

"KVUE (most recent quarter ended 2025-12-28) reported Revenue of $3.78B and Net Income of $330M, with EPS of $0.17. On a YoY basis, Revenue grew ~3.2% (vs. $3.66B in 2024-12-31) while Net Income increased ~12.6% (vs. $293M). QoQ, Revenue was essentially flat (+0.4%), but Net Income declined ~17.1% (vs. $398M in 2025-09-28). Net income margin contracted QoQ (about 8.7% vs. 10.6%), though it remains slightly improved vs. a year ago (about 8.0%). Balance sheet resilience looks steady: Total Assets were $27.1B, slightly down QoQ, while Equity improved to $10.8B. Net Debt eased to ~$7.46B from ~$7.97B QoQ, supporting flexibility. KVUEโ€™s shareholder returns are mixedโ€”price momentum is weak, with a -22.5% 1-year change, partially offset by a dividend yield around 3.6% (dividend stability implied by regular payments). No buyback data was provided, so total return is mainly dividend + market performance. Analyst targets suggest modest upside: consensus target $18.17 vs. $17.61 current (~3% upside). Overall, fundamentals are stable but profitability softness in the latest quarter limits the score."

Revenue Growth

Neutral

Revenue was nearly flat QoQ (+0.4% from $3.76B to $3.78B) and modestly higher YoY (+3.2% from $3.66B to $3.78B), indicating steady but not accelerating growth.

Profitability

Caution

Net Income fell QoQ (-17.1% from $398M to $330M) despite YoY improvement (+12.6%). Net income margin contracted QoQ (โ‰ˆ8.7% vs. 10.6%), signaling profitability pressure in the latest quarter.

Cash Flow Quality

Neutral

Net Income increased YoY, supporting earnings power. Dividend yield is meaningful (~3.6%), with historical payout ratio shown as low-to-moderate at times; buyback/cash flow detail was not provided, limiting assessment of cash conversion.

Leverage & Balance Sheet

Positive

Total Assets are stable/slightly down QoQ, Equity improved QoQ ($10.65B to $10.77B), and Net Debt decreased to ~$7.46B from ~$7.97B, indicating improving leverage/resilience.

Shareholder Returns

Caution

1-year price performance is weak (-22.5%), which likely outweighs dividend income. Dividend yield (~3.6%) provides some cushion, but total return appears negative overall without evidence of strong buybacks.

Analyst Sentiment & Valuation

Neutral

Consensus target ($18.17) is modestly above the current price ($17.61), implying limited upside (~3%). Valuation appears supported but not clearly discounted given profitability volatility.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Kenvue reported a disappointing Q2 with organic sales down 4.2% and adjusted EPS of $0.29, prompting a reduction to full-year 2025 guidance. Management acknowledged execution shortfalls and category deceleration, while noting that consumption outpaced reported sales across segments and that share trends in Self Care were strong. Skin Health showed sequential improvement, with Neutrogena Face returning to growth in the U.S., and EMEA/Latin America remained relative bright spots. A new interim CEO and CFO outlined a back-to-basics plan focused on simplifying the portfolio, improving execution, modernizing systems, and strengthening revenue growth management. The Boardโ€™s strategic alternatives review, including potential portfolio optimization, is underway. Overall tone was urgent and action-oriented, but cautious given near-term headwinds and the need to restore consistent, reliable performance.

Growth

  • Organic sales declined 4.2% YoY; global consumption was positive and outpaced reported organic sales across all segments.
  • Self Care: U.S. performance strong on shareโ€”83% of the business held or gained share; Zyrtec increased household penetration across adult and children franchises.
  • Skin Health & Beauty: U.S. Neutrogena Face returned to YoY consumption growth; global consumption stabilized with growth in EMEA, Latin America, and APAC.
  • Essential Health: Strength in Latin America; declines in other regions versus a strong prior-year compare.
  • Most robust innovation pipeline in years scheduled for the back half of 2025.

Business Development

  • Board initiated a comprehensive review of strategic alternatives; strategic review committee formed (CEO is a member).
  • Potential optimization of the brand portfolio under consideration as part of the review.
  • Global Listerine 'Wash Your Mouth' marketing campaign launched in the U.S. and activated in Canada, U.K., Germany, and China.

Financials

  • Organic sales: -4.2% YoY (below expectations).
  • Adjusted operating margin: 22.7% (down 10 bps YoY), with SG&A savings partly offsetting softer gross margins.
  • Adjusted diluted EPS: $0.29 vs $0.32 in the prior year period.
  • Company revised full-year 2025 guidance lower (specifics not disclosed on the call excerpt).
  • Categories decelerated sequentially vs Q1 and YoY; execution below expectations compounded results.

Capital & Funding

  • Focus on improving cash flow conversion via working capital initiatives (inventory and payables) as supply chain transformation progresses.
  • Targeting additional SG&A cost savings to reach peer benchmark levels and fund growth investments.
  • No specific updates on dividends, buybacks, or new financing disclosed in the call excerpt.

Operations & Strategy

  • Immediate priorities: strengthen leadership and capabilities; simplify operating strategy; elevate execution; optimize structure and operating model for speed and agility.
  • Reducing complexity across brands/SKUs/marketsโ€”of 115 brands, 41 drive over three-quarters of sales; long-tail SKUs comprise a large share of SKUs but ~1% of sales.
  • Sharpened focus on winning with largest brands and customers in top markets (top 10 brands per region >2/3 of sales; top 10 markets >3/4 of sales).
  • Consumer-centric approach to drive household penetration, brand building, and innovation; stronger revenue growth management, category management, perfect-store, and e-commerce execution.
  • Modernizing systems, processes, and technologies; enhancing integrated business planning and consumption-driven demand forecasting.

Market & Outlook

  • Dynamic macro backdrop with category deceleration versus Q1 and YoY.
  • EMEA and Latin America cited as relative bright spots; U.S. Skin Health consumption trends improved sequentially.
  • Self Care impacted by soft allergy season and customer inventory dynamics, masking underlying share gains.
  • Back-half 2025 innovation slate expected to be the most robust in years.
  • Full-year 2025 outlook revised down reflecting Q2 results and current expectations.

Risks Or Headwinds

  • Customer inventory adjustments and unfavorable seasonality in key categories (e.g., allergy).
  • Execution gaps and organizational complexity (brand/SKU proliferation) impacting agility and results.
  • Category growth deceleration in core markets.
  • Transition and systems modernization risks as the company moves off legacy infrastructure.
  • Potential disruption and uncertainty as strategic alternatives are evaluated.

Sentiment: CAUTIOUS

Note: This summary was synthesized by AI from the KVUE Q2 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
๐Ÿ“

SEC Filings (KVUE)

ยฉ 2026 Stock Market Info โ€” Kenvue Inc. (KVUE) Financial Profile